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471JACC Vol. 47, No. 2, 2006 Correspondence
January 17, 2006:464–71ion, and practice to refer patients for subsequent repeat catheter-
zation and revascularization procedures will also minimize the
ractical relevance of any differences in late loss. In the end,
robably all would agree that, up to a point, less late loss is better,
ut the range of late loss that is associated with infrequent clinically
riven TLR may be wider than previously believed. Whether this
elationship holds in more complex and challenging lesion subsets
ill be analyzed in the TAXUS-V and -VI studies.
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lthough we appreciate the interest by Dr. Ellis and colleagues toward
ur recent editorial comment (1), we fear a central concept was missed.
he argument that more late loss (as long as the absolute measure
emains below some arbitrary threshold) is irrelevant as a measure of
rug-eluting stent (DES) efficacy is both intuitively flawed and derived by
n erroneous extrapolation from individual patient-level observations to
ean late loss values. Across observed levels of mean late loss in recent
rials, incremental changes in late loss are associated with increasing
estenosis risk (2). The relationship of mean late loss values to clinical
estenosis does not follow the S-shaped curve presented by Dr. Ellis and
olleagues but instead is curvilinear without an obvious inflection point
2). Furthermore, results of randomized controlled clinical trials compar-
ng the Cypher and Taxus stents for treatment of coronary stenoses in
Table 1. Randomized Comparative Trials of C
Trial
Late Lumen Loss
(mm)
Cypher Taxus
ISAR-DIABETES 0.19 0.45
SIRTAX 0.13 0.25
REALITY 0.09 0.31
ISAR-DESIRE 0.10 0.26omplex patient subsets do not support the “threshold” premise (3–6).
lthough the ISAR–DIABETES, SIRTAX, REALITY, and ISAR–
ESIRE trials reported mean late loss values well below the 0.75 mm
threshold” for clinical significance set by Dr. Ellis and colleagues, the
bserved binary angiographic restenosis (BAR) and target lesion revas-
ularization (TLR) rates were increased in proportion to increases in late
oss (Table 1). If coronary stents are deployed in one million individuals
early, the relative percent differences in BAR and TLR observed in these
rials translate into large socioeconomic differences (50,000 more
evascularization procedures yearly) and clearly support the premise that
less is better” with respect to late lumen loss in the DES era.
As we predicted in our editorial, when DES with apparent
ubtle differences in late lumen loss are compared, differences in
ate clinical/angiographic outcome measures are magnified in those
atient cohorts with the greatest propensity for restenosis. Thus,
ate lumen loss remains a primary measure of stent efficacy, which
orrelates with late clinical/angiographic outcomes in the DES era.
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r Versus Taxus Stents
BAR
(%)
TLR
(%)
Cypher Taxus Cypher Taxus
6.9 16.5 6.4 12.0
6.7 11.9 4.8 8.3
9.6 11.1 5.0 5.4yphe14.3 21.7 8.0 19.0
